Head-to-head · computed 2026-08-11
bmiMD vs Gala GLP-1
bmiMD: bmiMD is a compounded GLP-1 telehealth platform notable for flat per-dose pricing — the rate stays the same whether you're at 2.5 mg or 15 mg — and one of the widest plan-tier menus in the market. Its $99/mo semaglutide and $139/mo tirzepatide on the twelve-month plan are the lowest annualized figures in the dataset for both molecules. Gala GLP-1: Gala GLP-1 is an all-50-state compounded GLP-1 service offering a range of pricing by product tier, including a microdosing option. Its standard all-dose rate is $179/mo (tirz) and $179/mo (sema) with a microdosing tier starting at $149.
Tirzepatide
| bmiMD | Gala GLP-1 | |
|---|---|---|
| All-in maintenance | $179/mo | $179/mo |
| Best plan rate | $139/mo | $179/mo |
| 12-month total | $1,668 | $2,148 |
| Status | Reported · 2026-07-14 | Reported · 2026-07-14 |
The arithmetic
On monthly cost the two are tied at $179; the decision comes down to structure — bmiMD's (flat — same price at every dose, across all plan lengths) against Gala GLP-1's (flat at 'all doses' for standard plan; separate microdosing tier at $149).
bmiMD's tirzepatide ladder runs $179 a month billed monthly, $159 a month on a three-month plan, $149 a month on a six-month plan, and $139 a month on a twelve-month plan. Gala GLP-1's runs $179 a month billed monthly, and $199 a month on a three-month plan. On the twelve-month basis bmiMD's $1,668 beats Gala GLP-1's $2,148 by $480 — with the winner's figure resting on a committed twelve-month plan, a structural difference that matters if you might stop early.
Semaglutide
| bmiMD | Gala GLP-1 | |
|---|---|---|
| All-in maintenance | $129/mo | $179/mo |
| Best plan rate | $99/mo | $179/mo |
| 12-month total | $1,188 | $2,148 |
| Status | Reported · 2026-07-14 | Reported · 2026-07-14 |
The arithmetic
On the figures our desk holds, bmiMD's $129 a month undercuts Gala GLP-1's $179 by $50 a month at the 2.4 mg/wk maintenance basis — $600 across a year. bmiMD's figure is reported (captured 2026-07-14) and Gala GLP-1's is reported (captured 2026-07-14); a status below 'verified' means our independent checkout capture is still pending, so treat the gap as the best current evidence rather than settled fact.
bmiMD's semaglutide ladder runs $129 a month billed monthly, $119 a month on a three-month plan, $109 a month on a six-month plan, and $99 a month on a twelve-month plan. Gala GLP-1's runs $179 a month billed monthly, and $199 a month on a three-month plan. On the twelve-month basis bmiMD's $1,188 beats Gala GLP-1's $2,148 by $960 — with the winner's figure resting on a committed twelve-month plan, a structural difference that matters if you might stop early.
Structure, side by side
bmiMD
- MembershipNone
- Dose policyFlat — same price at every dose, across all plan lengths
- CommitmentMonthly, 3-month, 6-month, or 12-month plans; price varies by term, not by dose
- CancellationPer provider terms; confirm cancellation policy at enrollment
- PharmacyNamed 503A pharmacy partner (specific pharmacy not publicly identified on pricin
Gala GLP-1
- MembershipNone
- Dose policyFlat at 'all doses' for standard plan; separate microdosing tier at $149
- Commitment3-month plan or standard monthly; confirm exact terms at enrollment
- CancellationPer provider terms
- PharmacyPartner 503A pharmacies (not named publicly)
What our desk is watching on each
bmiMD: bmiMD's 12-month semaglutide plan at $99/mo is the lowest annualized sema figure in our dataset, beating NexLife's $119/mo and Oak's $133 m2m. Month-to-month sema at $129 also beats Oak's $133, making bmiMD the new m2m sema leader. Tirzepatide 12-month at $139 ties NexLife. Figures are reported status from RangeYourself's July 2026 first-party captures; our independent checkout is pending.
Gala GLP-1: Gala lists a range rather than one fixed price: the hero says $179/mo 'all doses', the FAQ says $199/mo 'with a 3-month plan', and $149/mo is listed for microdosing. This makes 'all-in maintenance' ambiguous; we rank on the $179 standard figure with a note. Exact ongoing rate must be confirmed at enrollment. Reported status from RangeYourself 2026-07-14.
Questions people ask
Is bmiMD or Gala GLP-1 cheaper in 2026?
The tirzepatide and semaglutide verdict blocks above give the computed answer at the maintenance basis, with the verification status of each figure; the short version is that whichever program's all-in monthly number is lower on this page is cheaper on the evidence we hold today, and both rows carry capture dates so you can judge freshness.
What does bmiMD vs Gala GLP-1 miss that checkout will show?
Taxes, state availability, current promotions, and any dose surcharge introduced after our capture date. Screenshot the order summary before paying — that capture, not any comparison page, is your contract.
Why do you compare at the maintenance dose instead of the starting dose?
Because starter pricing lasts one or two months and maintenance pricing lasts the rest of the year; comparing starts against maintenances is the single most common way GLP-1 comparisons mislead.
What do bmiMD and Gala GLP-1 cost over a full year of tirzepatide?
On the plans our database holds, a year of tirzepatide runs $1,668 at bmiMD and $2,148 at Gala GLP-1 — computed from each program's best published twelve-month route, with promotional figures labeled in the sections above and every number carrying its capture date.
Both records live in the normalized database; re-run the math yourself from the downloads. Full record pages: bmiMD · Gala GLP-1. Official sites: bmiMD ↗ · Gala GLP-1 ↗. Nothing here is medical advice.